Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
SL

NASDAQ · SLP

Simulations Plus, Inc.

Healthcare · Medical - Healthcare Information Services

$18.50

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 5:21 AM

SID Score

6.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
393.22M
P/E ratio
-6.21
Dividend yield
0.00%
52-week range
$11.09 – $18.68
Volume
625.31K
Avg. volume
511.28K

Price performance · SLP

SLP price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 5, 2026

SLP closed at $18.50 after 20 trading sessions, up 0.43% for the selected period.

Last close
$18.50
Period change
+0.43%
Period low
$18.41
Period high
$18.50
Daily close
View OHLC price history
SLP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 5, 2026$18.50$18.50$18.49$18.50625.31K
Oct 2, 2026$18.50$18.50$18.49$18.50460.26K
Oct 1, 2026$18.47$18.50$18.45$18.49865.86K
Sep 30, 2026$18.47$18.48$18.43$18.43332.44K
Sep 29, 2026$18.47$18.49$18.47$18.48137.13K
Sep 28, 2026$18.45$18.48$18.45$18.48138.5K
Sep 25, 2026$18.45$18.47$18.435$18.46131.28K
Sep 24, 2026$18.42$18.46$18.41$18.46433.36K
Sep 23, 2026$18.42$18.42$18.41$18.42104.38K
Sep 22, 2026$18.45$18.45$18.41$18.41232.13K
Sep 21, 2026$18.44$18.45$18.42$18.43224.19K
Sep 18, 2026$18.43$18.44$18.43$18.44134.12K
Sep 17, 2026$18.44$18.45$18.43$18.4469.08K
Sep 16, 2026$18.41$18.44$18.40$18.43166.52K
Sep 15, 2026$18.42$18.42$18.40$18.41116.38K
Sep 14, 2026$18.42$18.43$18.41$18.42249.37K
Sep 11, 2026$18.42$18.43$18.42$18.42133.57K
Sep 10, 2026$18.42$18.43$18.42$18.42187.88K
Sep 9, 2026$18.44$18.44$18.42$18.42181.15K
Sep 8, 2026$18.43$18.44$18.42$18.42156.75K

Latest SLP news

The latest Smart Investors Daily articles mentioning SLP.

Stock researchCompany · Overview

SLP research

Overview

Company profile and research snapshot.

Company profile

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$56.00
Implied upside
—
Analysts
11
SLP recent ratings
DateFirmRatingTarget
Jun 17, 2026William BlairMarket Perform—
Apr 10, 2026TD CowenHold—
Jan 8, 2026TD CowenHold—
Dec 18, 2025BTIGNeutral—
Sep 30, 2025TD CowenHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 17, 2026

Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch

RESEARCH TRIANGLE PARK, N.C., September 17, 2026--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that the U.S. Food and Drug Administration’s (FDA) Cosmetics Regulatory Science Branch has licensed ADMET Predictor® to support its computational research for modern cosmetic safety assessment. The contract expands the use of Simulations Plus technolog

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By